Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Prostatype Genomics AB's Enterprise Value is kr36.10 Mil.
Prostatype Genomics AB's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was kr-39.38 Mil. Therefore, Prostatype Genomics AB's EV-to-EBIT ratio for today is -0.92.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Prostatype Genomics AB's Enterprise Value is kr36.10 Mil.
Prostatype Genomics AB's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 was kr-37.40 Mil. Therefore, Prostatype Genomics AB's EV-to-EBITDA ratio for today is -0.97.
Prostatype Genomics AB Enterprise Value Historical Data
The historical data trend for Prostatype Genomics AB's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Prostatype Genomics AB's Enterprise Value
For the Diagnostics & Research subindustry, Prostatype Genomics AB's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prostatype Genomics AB's Enterprise Value Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Prostatype Genomics AB's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Prostatype Genomics AB's Enterprise Value falls into.
Prostatype Genomics AB Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Prostatype Genomics AB's Enterprise Value for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Prostatype Genomics AB (OSTO:PROGEN) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Prostatype Genomics AB's current Enterprise Value is kr36.10 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Prostatype Genomics AB's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was kr-39.38 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Prostatype Genomics AB's EV-to-EBITDA for today is:
Prostatype Genomics AB's current Enterprise Value is kr36.10 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Prostatype Genomics AB's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 was kr-37.40 Mil.
Prostatype Genomics AB's current Enterprise Value is kr36.10 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Prostatype Genomics AB's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 was kr0.20 Mil.
Prostatype Genomics AB's current Enterprise Value is kr36.10 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Prostatype Genomics AB's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was kr-52.57 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Prostatype Genomics AB Enterprise Value Related Terms
Thank you for viewing the detailed overview of Prostatype Genomics AB's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. By assessing the aggressiveness of prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
OSTO:PROGEN has been successfully added to your 